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Abstract
Background: Exposure of pregnant mothers to elevated concentrations of circulating testosterone levels is
associated with fetal growth restriction and delivery of small-for-gestational-age babies. We examined whether
maternal testosterone crosses the placenta to directly suppress fetal growth or if it modifies placental function to
reduce the capacity for transport of nutrients to the fetus.
Methods: Pregnant rats were exposed to testosterone propionate (TP; 0.5 mg/kg) by daily subcutaneous injection
from gestational days (GD) 15-19. Maternal and fetal testosterone levels, placental nutrient transport activity and
expression of transporters and birth weight of pups and their anogenital distances were determined.
Results: This dose of TP doubled maternal testosterone levels but had no effect on fetal testosterone levels.
Maternal daily weight gain was significantly lower only on GD 19 in TP treated dams compared to controls.
Placental weight and birth weight of pups were significantly reduced, but the anogenital distance of pups were
unaffected by TP treatment. Maternal plasma amino acids concentrations were altered following testosterone
exposure, with decreases in glutamine, glycine, tyrosine, serine, proline, and hydroxyproline and increases in
asparagine, isoleucine, leucine, lysine, histidine and arginine. In the TP dams, placental system A amino acid
transport activity was significantly reduced while placental glucose transport capacity was unaffected. Decreased
expression of mRNA and protein levels of slc38a2/Snat2, an amino acid transporter, suggests that reduced
transporter proteins may be responsible for the decrease in amino acid transport activity.
Conclusions: Taken together, these data suggest that increased maternal testosterone concentrations do not cross
the placenta to directly suppress fetal growth but affects amino acid nutrient delivery to the fetus by
downregulating specific amino acid transporter activity.
Background
Elevated testosterone levels during pregnancy is shown
to be associated with low birth weight in humans and
animals [1-5]. Women experiencing hyperandrogenism
associated with polycystic ovarian syndrome (PCOS)
[6,7] and preeclampsia [8-10] have a higher-than-normal
prevalence of small-for-gestational age deliveries [11-15].
In animal models, such as rat and sheep, testosterone
exposure during pregnancy leads to a dose-dependent
reduction in birth weight of fetuses [1,3,16,17]. In
addition to causing low birth weight, hyperandrogen-
emia during pregnancy also poses an increased risk for
the development of cardiovascular and metabolic dys-
functions later in life for both the child and the mother
[18-21]. Despite findings that excess androgen during
pregnancy influences fetal growth restriction and pro-
gramming of metabolic tissues, there are no studies that
have examined the underlying mechanisms. An under-
standing of such mechanisms will aid in the develop-
ment of effective interventions to improve mother’s
health and decrease or perhaps prevent conditions that
lead to the birth of small-for-gestational-age babies and
the consequent risk of complications in adult life.
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sheep does not affect the mother’s food intake [17,22]
or alter levels of other important pregnancy-related hor-
mones, such as estradiol, progesterone, corticosterone,
insulin, leptin, thyroid hormones (total T3, total T4, and
free T4) and IGF1 [17,22]. Testosterone exposure during
pregnancy in rats and sheep was also found not to affect
maternal blood levels of glucose, triglycerides and cho-
lesterol [22,23]; thus, testosterone-induced fetal growth
restriction may not be secondary to alterations in the
mother’s metabolic status.
Testosterone is lipophilic and is suggested to diffuse
through the placenta [24-26]t oe x e r tad i r e c te f f e c to n
fetal growth and/or energy homeostasis. Alternatively
testosterone may affect normal placental development
and function [27]. The crucial role of the placenta dur-
ing fetal development is thought to depend on the
transplacental exchanges of oxygen and nutrients, as
well as waste between the closely apposed maternal and
fetal circulatory systems [28]. The placenta is also an
endocrine target, expressing a broad spectrum of hor-
mone receptors including androgen receptors [29];
hence, testosterone may modify placental function and
reduce the capacity for transport of nutrients to the
fetus. In this study, we evaluated whether maternal tes-
tosterone crosses the placenta to directly affect fetal
growth or testosterone modifies placental development
and function to affect nutrient transport capacity to the
fetus. Our studies show that an increase in circulating
maternal testosterone levels in pregnant rats at a clini-
cally relevant concentration (2-fold–similar to that
observed in human pregnancies complicated with IUGR
[6-10]) induced fetal growth restriction without increase
in fetal testosterone levels, but it is associated with a
reduction in placental amino acid transport activity, pos-
sibly through a decrease in expression of the slc38a2/
Snat2 amino acid transporter.
Methods
Animals
Timed-pregnant Sprague-Dawley rats (Harlan, Houston,
TX) were received on gestational day (GD) 12 (GD 1 =
day of sperm-positive smear) and housed 2 per cage in
polycarbonate cages. They were acclimated to 68-74°F
and 40-50% relative humidity ( 1 2h o u r s ,l i g h t : 1 2h o u r s ,
dark) and given a Prolab RMH 2500 diet (high-energy
diet for gestation and lactation) and tap water ad libi-
tum. On GD 14, the dams were randomly assigned to 2
treatment groups. The pregnant rats received daily
doses from GD 15-19 by subcutaneous (sc) injection
with either vehicle (n = 24) or 0.5 mg/kg TP (n = 24;
Sigma, St. Louis, MO) suspended in 0.1 ml sesame oil.
We and others have shown that TP treatment to preg-
nant rats leads to a dose-dependent reduction in birth
weight of fetuses [1,17,30]. For this study, we elected to
use this dosing regimen, since it caused a 2-fold increase
in circulating maternal testosterone levels [17] similar to
that observed in human pregnancies complicated with
fetal growth inhibition [6-10]. Because an increase in
testosterone levels during the later stage of pregnancy
was shown to be associated with IUGR [5] and pree-
clampsia [31,32], we chose this time period (GD 15-19)
of TP treatment in pregnant rats.
Maternal weight was monitored throughout the dosing
period. In Experiment #1, the pregnant rats were sacri-
ficed 2 hours after last TP dose on GD 19 (at plateau
circulating testosterone concentration [1,33,34] to mea-
sure maternal/fetal testosterone levels; n = 6 in each
group). In Experiment #2,t h ep r e g n a n tr a t sw e r es a c r i -
ficed on GD 21 (the period of active placental function)
to determine placental nutrient transport capacity (n =
6, each group). In Experiment #3, spontaneous vaginal
delivery was allowed for some dams (n = 6, each group)
to determine birth weight and anogenital distance
(AGD), an indicator of androgenicity [35]. All proce-
dures were approved by the Institutional Animal Care
and Use Committee at The University of Texas Medical
Branch (UTMB).
Experimental Design
Experiment 1: Maternal/fetal testosterone Levels
On GD 19, 2 hours after dosing, 6 control and 6 TP
dams were euthanized by CO2 asphyxiation. Maternal
blood and fetuses were collected no earlier than 2 hours
after dosing to allow the TP to undergo distribution and
metabolism and reach plateau testosterone levels in
both the dams and fetuses [1,33,34]. Each dam was
euthanized and its fetuses collected before the next dam
was euthanized. Maternal blood was collected by heart
puncture. Fetuses were removed from the uterus, held
on ice in a small plastic petri dish, and saved in 15-ml
plastic, round-bottomed Falcon tubes (Becton-Dickin-
son, Lincoln Park, NJ). Fetuses were stored at -20°C for
~1 week at which time they were extracted and assayed
for testosterone levels. Maternal blood was centrifuged
and plasma was stored at -70°C for 1 week until it was
assayed for testosterone levels. Storage of fetuses or
plasma for this time period did not cause any significant
loss in testosterone levels. In addition to the above men-
tioned TP dose (0.5 mg/kg/day; n = 5), a lower dose (0.1
mg/kg/day; n = 5) and a higher dose (2.5 mg/kg/day; n
= 5) were also administered to a separate set of dams
w h e r en oc h a n g eo rad e f i n i t i ve increase in maternal/
fetal testosterone level, respectively was expected.
DNA extraction from fetus and sex determination
Genomic DNA was extracted from a piece of fetal tissue
(hind limb) and tails of adult male and female rats (as
controls) with Qiagen DNeasy Blood & Tissue Kit
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protocol. Sex determination was described by Kuddus et
al [36]. Males were determined by the presence of the
Sry gene in genomic DNA with 1 μg DNA template
added in polymerase chain reactions (PCR) and females
by no Sry gene amplification. The sequence of forward
primers for the Sry gene was 5’-cacaagttggctcaacagaatc-
3’ and reverse primer 5’-agctctactccagtcttgtccg-3’.G e n o -
mic DNA (1 μg) from adult males and females was
included as either a positive or negative control for the
PCR procedure. The PCR conditions were as follows: 1)
94°C for 5 minutes; 2) 94°C for 1 minute, 54°C for 2.5
minutes, and 72°C for 1 minute for 36 cycles; and 3) 72°
C for 7 minutes.
Fetal testosterone extraction Testosterone was
extracted from the fetus as described previously [1,37].
Fetuses were thawed and homogenized individually in
500-μl distilled and deionized water with a Polytron
homogenizer (Brinkmann Instruments, Westbury, NY).
After homogenization, 3 ml ethyl ether (Fisher Scientific,
Pittsburgh, PA) was added to each tube, and tubes were
vortexed for 30 seconds, and centrifuged at 2000 rpm
(1000 × g) at 8°C for 10 minutes. Following centrifuga-
tion, each tube was held 1 at a time in an acetone/dry
ice bath until the bottom aqueous layer froze, and the
supernatant (ether layer) was then transferred to a 12- ×
75-mm glass tube. Ether extraction was performed
twice, and glass tubes of ether extract were dried in a
fume hood overnight. Tubes were stored at -20°C until
analysis by radioimmunoassay.
Radioimmunoassay (RIA) of testosterone Each tube of
dried fetal extract was re-suspended by vortexing for 30
seconds in 70 μl of assay buffer provided in the Testos-
terone double antibody RIA kit #07189102 (MP Biome-
d i c a l s ,S o l o n ,O H ) .N e x t ,5 0μlo ft h e7 0 - μl fetal
resuspension were transferred to the tubes in the RIA
kit, and testosterone levels were determined according
to the manufacturer’s protocol. Tubes were read for 1
minute each in a Cobra gamma counter (Packard
Instrument Co., Downers Grove, IL). The maternal
serum was vortexed, and 50 μl of undiluted and diluted
plasma (1:2) assayed in duplicate by RIA for testosterone
following the testosterone RIA kit protocol. Fetal testos-
terone levels were expressed as ng/g of fetus (these data
represent 3 males or females per litter per dose group)
and maternal plasma testosterone levels were expressed
as ng/ml. Intra- and interassay coefficients of variation
for testosterone were 3% and 5% and sensitivity was
0.04 ng ml
-1.
Experiment 2: Placental nutrient transport capacity
On GD 21, maternal blood and placenta were collected
from control and TP dams (n = 6 in each group).
Maternal plasma was used for determination of amino
acid concentrations and placentas were processed for
protein and RNA analysis. The placental RNA and pro-
tein samples of each dam constituted a pooled sample
isolated from 3 placentas per dam. In a separate set of
control and TP pregnant rats, placental transport mea-
surements were carried out (n = 6 in each group).
Analysis of amino acid concentrations in maternal
plasma Plasma amino acids were measured at Protein
Chemistry core lab at UTMB. Briefly, free amino acids
were analyzed by using ion exchange HPLC (Hitachi
model L-8800 amino acid analyzer; Hitachi, Inc., Plea-
santon, CA) equipped with columns (number 2622: 4.6
× 40 mm + 4.6 × 40 mm, Hitachi, Tokyo, Japan) and by
gradient elution with MCI buffer L-8500-PF kit (Wako,
Osaka, Japan). Amino acids post labeled with ninhydrin
were detected by measuring absorbance at 440 and
570 nm.
Implantation of vascular catheters Transport measure-
ments were carried out as previously described for the
awake pregnant rats [38]. Animals were anesthetized
with a mixture of ketamine (45 mg/kg; Burns Veterinary
Supply, Westbury, NY) and xylazine (5 mg/kg; Burns
Veterinary Supply) intraperitoneally. A 2-cm midline
incision was performed, and the right carotid artery and
right jugular vein were localized and catheterized with
PE 50 tubing. Subsequently, catheters were tunneled
subcutaneously to the neck where they emerged, filled
with heparinized saline (500 IU ml
-1), and plugged.
After awakening, animals were returned to the animal
facilities where they were left overnight to fully recover.
Transport measurements Placental transport was stu-
died as described by Coan et al [38], using the intrave-
nous administration of 3-O-methyl-D-[
3H]glucose (50
μCi kg
-1)a n d[
14C]methylaminoisobutyric acid (10 μCi
kg
-1). 3- O -Methyl-D-glucose and a-(methylamino)iso-
butyric acid are nonmetabolizable model substrates used
for characterization of the D-glucose and system A
amino acid transport system, respectively. These iso-
topes are extensively used to examine glucose and
amino acid transport across placenta [38,39]. After the
administration of isotopes, the rat was placed in a cage
where it was free to walk around for 6 minutes, when
an arterial blood sample (0.5 ml) was withdrawn for
determination of radioactivity in plasma. Seven minutes
after the infusion of isotopes, 1 ml ketamine (50 mg ml
-
1) was injected into the venous catheter to kill the ani-
mal. This time point was chosen based on previous
reports [38] demonstrating low feto-maternal backflux
of isotopes up to at least 7 minutes after isotope injec-
tion. The placentas and fetuses were weighed individu-
ally. Subsequently, fetuses and placentas from each litter
were pooled and cut into small pieces and homogenized
in three volumes of distilled water. Homogenates were
mixed with trichloroacetic (20%, 1:3), and the vials were
c e n t r i f u g e da t1 20 0 0gf o r1 0m i n u t e s .L i q u i d
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Analytic, Frankfurt, Germany) was added to 3 ml of
supernatant. Distilled water (3 ml) was added to 150-μl
plasma samples, followed by 12 ml of scintillation fluid.
Vials were shaken for 30 minutes prior to b-counting in
a liquid scintillation counter.
Real-time PCR Total RNA was extracted from placenta
by using RNeasy extraction kits (Qiagen, Valencia, CA).
The RNA (1 μg) was reverse transcribed into cDNA
(QuantiTect Rev. Transcription Kit; Qiagen). Quantita-
tive real-time PCR analysis was performed with an ABI-
PRISM 7700 real-time machine (Applied Biosystems
Inc., Foster City, CA), using a SYBR Green detection
system (Applied Biosystems) at UTMB’s Sealy Center
for Cancer Cell Biology core facility. Published primer
sequences [40] were used to measure the relative mRNA
amounts of the slc38a1, 2,a n d4.T h er e a c t i o n sw e r e
first incubated at 50°C for 30 min followed by 95°C for
15 min and then amplification of 35 cycles of each at
95°C for 15 s, 60°C for 60 s for slc38a1, and 2, and 62.8°
C for 60 s for slc38a4. The primers utilized were
slc38a1: (forward 5’-TCAGCCTGGTACGTCGATGG-3’,
reverse 5’-CCAGGTTCTTCAAGAGACACAG-3’),
slc38a2: (forward 5’-AGAGCAATTCCAGTATTAGC-3’,
reverse 5’-TTAATCTGAGCAATGCGATTGTG-3’), and
slc38a4 (forward 5’-GGCAGTGGTGTGGAGTAC-
GAAGC-3’,r e v e r s e5 ’-TGGAATCGCGTAGGCCGTG-
3’). After PCR, melting curves were acquired by stepwise
increase of the temperature from 55°C to 95°C to ensure
that a single product was amplified in the reaction.
Western blot Placentas were homogenized on ice in
buffer containing (mM): Tris-Hepes 10, sucrose 250,
and EDTA 1, and 1.6 μMa n t i p a i n ,0 . 7μM pepstatin,
and 0.5 μgm l
-1 aprotinin. Protein concentrations were
determined by the Bradford assay. Equal amounts of
protein (25 μg) were loaded onto 10% polyacrylamide
gels and electrophoresed at 200 V. The separated pro-
teins were transferred overnight onto a nitrocellulose
membrane. The membranes were blocked in blocking
buffer (5% nonfat dry milk) and then incubated over-
night with primary antibodies (1:500 for Snat1, 1:5000
for Snat2 and 1:1000 for Snat4; Snat1 and Snat4 anti-
body was a generous gift from Drs. Jean Jiang and Tho-
mas Jansson, respectively, University of Texas Health
Science Center San Antonio. Snat2 antibody was a gen-
erous gift from Dr. P.D. Prasad, Medical College of
Georgia). Peroxidase-labeled, anti-rabbit IgG (1:1000;
Vector Laboratories, Burlingame, CA) was used as a sec-
ondary antibody. The final detection was accomplished
by using enhanced chemiluminiscence (Pierce Biotech-
nology, Rockford, IL) to visualize signals on autoradio-
graphic film (Hybond, Amersham). The relative density
of the bands was evaluated by densitometry with alpha-
ease software. All chemicals were purchased from
Sigma-Aldrich Co. (St. Louis, MO) unless otherwise
noted.
Experiment 3: Birth weight of pups and their anogenital
distances
Pregnant rats were allowed to deliver spontaneously.
Immediately after birth, the pups (n = 6 litters in each
group) were counted, weighed, and sexed based on ano-
genital distances (AGD). The AGD in each male and
female pup was measured in a blind fashion under a dis-
secting microscope using calipers [41].
Statistical analysis
Transport data were presented as placental disintegra-
tions per minute (dpm) per gram placenta (representing
placental uptake of isotope), fetal dpm per gram fetus
(representing the amount of isotope transported per
gram fetus), and fetal dpm per gram placenta (giving a
measure of the amount of isotope transported per gram
placenta, i.e., the relative transport capacity of the pla-
centa). Transport data were expressed for the TP group
in relation to the controls where control values were
arbitrarily assigned a value of 1. To identify appropriate
endogenous housekeeping gene for analysis of real time
PCR data, the mRNA expression of several housekeep-
ing genes (beta actin, beta-2-microglobulin, glyceralde-
hyde-3-phosphate dehydrogenase, succinate
dehydrogenase complex (SDHA), ubiquitin C, and 18s
rRNA) were performed. In our experimental conditions,
18s and SDHA were found to be stably expressed across
control and TP placentas. Hence the abundance of the
target sequences was calculated relative to 18S rRNA
using the following formula: relative abundance = 2
-ΔCT,
where ΔCT is calculated as the difference between the
CT (threshold cycle) of the test sequences and of the
reference 18S rRNA sequence.
Since observations in individual pups and placentas of
the same litter were not independent, an average was
obtained for each litter. Therefore, n = 1 represents
averaged values in one litter, and all data presented as
mean ± S.E.M. Two-way ANOVA followed by Bonfer-
roni post hoc test was performed on multiple observa-
tions and unpaired Student’s t-test for comparison of
single observations between control and TP groups.
Data analysis was done using GraphPad Prism for Win-
dows (GraphPad Software, SanD i e g o ,C A ) .D i f f e r e n c e s
were considered statistically significant at P < 0.05.
Results
Maternal total weight gain during the dosing period was
not significantly different (P = 0.25) between control (61.4
± 3.54; n = 10) and TP dams (56.8 ± 2.03; n = 13). How-
ever, when expressed as daily weight gain through the dos-
ing period, TP dams gained significantly less (P <0 . 0 1 )
weight on GD 19 (12.5 ± 0.84 grams; n = 11) compared to
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no significant difference in litter size between control (12.1
± 0.46) and TP (11.3 ± 0.52) groups.
Experiment 1: Maternal and fetal testosterone levels
Maternal serum testosterone levels (in ng/ml) increased in
a dose-dependent fashion and were significantly elevated
(P < 0.05) at 0.5 (n = 6) and 2.5 mg/kg TP (n = 5) (Figure
2A). In contrast, fetal testosterone levels (in ng/fetus) rose
significantly (P < 0.05) only in the males and females at 2.5
mg TP (n = 5) and not at 0.5 mg TP (n = 6) (Figure 2B),
despite the increased testosterone levels in the dam at this
dose. The testosterone level in the male fetuses was higher
than that in the females across all treatments, a finding
consistent with previous reports [42].
Experiment 2: Placental nutrient transport function
Maternal plasma amino acid concentrations
There were no significant differences in the plasma con-
centration of some amino acids between control and TP
dams. Asparagine (+61%), isoleucine (+30%), leucine
(+27%), lysine (+37%), histidine (+63%) and arginine
(+75%) were significantly increased (P < 0.05) in TP
dams (n = 6) compared to controls (n = 6) (Table 1).
On the other hand, glutamine (-16%), glycine (-31%),
serine (-24%), tyrosine (-12%), proline (-23%), and
hydroxyproline (-80%) were significantly reduced (P <
0.05) in TP-exposed dams (n = 6) compared with con-
trols (n = 6) (Table 1).
Fetal and placental weights
On GD 21, the fetal weights were significantly lower by
7% and placental weights were significantly lower by
11% (P <0 . 0 5 ;n=6i ne a c hg r o u p )i nt h eT Pg r o u p
compared with controls (Table 2). There was no signifi-
cant difference in fetal-to-placental weight ratio between
control and TP groups (Table 2).
Placental uptake and transport of 3-O-methyl-D-[
3H]glucose
and [
14C]methylamino isobutyric acid (MeAIB)
The placental uptake (placental dpm per gram placenta)
and transport to the fetus (fetal dpm per gram fetus) of
3-O-methyl-D-[
3H]glucose were not altered by TP treat-
ment. Similarly, the placental transport activity (fetal
dpm per gram placenta) of 3-O-methyl-D-[
3H]glucose
was unchanged by TP treatment (Figure 3A). In con-
trast, placental uptake, placental transport, and placental
transport capacity of MeAIB were significantly reduced
(P < 0.05) by 20%, 26%, and 19%, respectively, in the TP
group compared with controls (Figure 3B; n = 6 in each
group).
Placental mRNA expression of Snat’s
We next examined if the decrease in amino acid trans-
port capacity is associated with a decreased expression
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Figure 1 Daily weight gain in control and TP dams.T Pw a s
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Figure 2 Maternal and fetal testosterone levels in control and
TP groups. Testosterone levels in dams and fetuses at gestational
day (GD) 19, after subcutaneous administration of 0, 0.1, 0.5, or 2.5
mg TP/kg (GD 15-19; n = 5-6). (A) Testosterone levels in dam
plasma. (B) Testosterone levels in fetal homogenates. Values
represent litter means. Data are expressed as mean ± SEM. *P <
0.05 vs controls.
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of system A present in the rat placenta, slc38a1, 2,a n d
4 [43]. Treatment with TP significantly reduced the
mRNA expression of slc38a2 (P < 0.05; n = 6 in each
group) (Figure 4B) in GD 21 placenta compared to con-
trols. However, mRNA expression of slc38a1 and
slc38a4 was not affected at GD 21 in the TP group
compared with the control group (Figure 4A and 4C).
Protein expression of Snat’s
We examined if the decreased mRNA levels of slc38a2
translated to reduced protein levels. Protein expression
of Snat2 in placental homogenates was reduced at GD 21
by 18% (P < 0.05) in the TP group (n = 6) compared to
control group (n = 6) (Figure 5). Snat2 antibody detected
two distinct bands at approximately 58 and 48 kDa in
Western blot. Antibody specificity was determined in
preadsorption experiments, and both these bands were
markedly attenuated (data not shown). For quantification,
densitometry values of both these bands were analysed
together. Protein expression of Snat1 and Smat4 in pla-
cental homogenates was similar at GD 21 in the TP and
controls placental homogenates (Figure 5).
Table 1 Amino acid concentrations in maternal plasma of
control (n = 6) and testosterone-exposed dams (n = 6).
Amino acid Control (n = 6) TP (n = 6) p value
Taurine 0.13 ± 0.001 0.13 ± 0.005 1
Phosphoserine 1.58 ± 0.059 1.30 ± 0.211 0.23
Aspartic acid 0.25 ± 0.037 0.25 ± 0.008 1
Therionine 3.66 ± 0.076 3.62 ± 0.167 0.83
Asparagine 0.72 ± 0.070 1.16 ± 0.080* 0.002
Glutamic acid 2.24 ± 0.423 2.65 ± 0.295 0.45
Glutamine 12.86 ± 0.227 10.82 ± 0.581* 0.008
Glycine 3.07 ± 0.142 2.11 ± 0.138* 0.0007
Alanine 7.48 ± 0.186 7.14 ± 0.230 0.28
Citrulline 0.90 ± 0.174 0.88 ± 0.087 0.92
Valine 1.67 ± 0.161 2.08 ± 0.219 0.16
Methionine 0.57 ± 0.026 1.10 ± 0.253 0.06
Cystine 0.14 ± 0.015 0.27 ± 0.073 0.11
Isolucine 0.93 ± 0.051 1.21 ± 0.088* 0.02
Leucine 1.61 ± 0.048 2.05 ± 0.174* 0.03
Tyrosine 0.66 ± 0.022 0.74 ± 0.015* 0.01
Phenylalanine 0.90 ± 0.092 0.97 ± 0.065 0.55
Ornithine 0.73 ± 0.009 0.86 ± 0.135 0.36
Lysine 7.68 ± 1.19 10.58 ± 0.431* 0.04
Histidine 0.30 ± 0.023 0.49 ± 0.059* 0.01
Arginine 1.61 ± 0.235 2.81 ± 0.035* 0.0005
Serine 4.05 ± 0.138 3.09 ± 0.139* 0.0006
Hydroxyproline 0.55 ± 0.034 0.114 ± 0.043* ≤ 0.0001
Proline 3.54 ± 0.229 2.72 ± 0.162* 0.015
*P < 0.05 versus control.
Table 2 Litter size, and fetal and placental weights on GD21.
Group n
litters
litter size (n) fetal weight
(g)
placental weight (g) Fetal-to-placental weight ratio (g/g)
Control 6 11.6 ± 0.42 3.69 ± 0.05 0.597 ± 0.002 6.24 ± 0.20
TP0.5 6 11.1 ± 0.58 3.42 ± 0.05* 0.534 ± 0.003* 6.40 ± 0.11
Means ± S.E.M. *P < 0.05 versus control group.
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Figure 3 Placental amino acid and glucose transport capacity
in control and TP dams. Placental Transport of (A)3 - O-methyl-D-
[
3H]glucose (MG) or (B)[
14C]methylaminoisobutyric acid (MeAIB) to
the fetus at GD 21. TP was administered prenatally (0.5 mg/kg;
gestational days 15-19) and placental uptake (placental (dpm) per
gram placenta), placental transport to the fetus (fetal dpm per gram
fetus) and placental transport capacity (fetal dpm per gram
placenta) of MG or MeAIB are expressed for the TP (n = 6) group in
relation to control (n = 6) where control values are arbitrarily
assigned a value of 1. Values are given as means ± S.E.M. *P < 0.05
vs controls.
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Page 6 of 12Experiment 3: Birth weight and AGD
Treatment of pregnant rats with TP caused a significant
reduction (P < 0.05; n = 8, each litter) in birth weight of
male and female pups by 14% and 11%, respectively,
compared with their respective gender in the vehicle-
treated group (Figure 6A). The AGD was larger in the
males and shorter in the females in control and TP
pups. Treatment by TP did not affect the mean AGD in
pups of either sex, when compared to their respective
gender in controls (Figure 6B).
Discussion
The present study demonstrated that a 2-fold increase
in maternal testosterone levels markedly reduced the
birth weight of both males and females pups compared
with controls. These findings indicate that elevated
maternal plasma testosterone concentrations, similar to
those observed in complicated human IUGR pregnan-
cies [11-15], have placental and fetal growth inhibitory
properties. Testosterone is a lipophilic hormone and is
suggested to diffuse across tissues including placenta
[24-26]; however increase in maternal plasma testoster-
one concentration, that caused fetal growth inhibition,
was not associated with increase in fetal body testoster-
one concentration or alteration in AGD (functional indi-
cator of androgenicity). This finding may indicate that
testosterone administered to the dam is not delivered to
the fetus, but is metabolized or blocked at the placenta
[27,44]. Rat placenta does not have aromatase enzyme
[45,46] to convert testosterone to estradiol but predomi-
nately expresses Δ
4-reductase and 17b-hydroxysteroid
dehydrogenase that metabolizes testosterone to weak
androgens such as 5a-androstane-3a-17b-diol [47] and
androsterone [27], respectively. Testosterone given to
the pregnant rat may be metabolized by the dam, pla-
centa and/or fetus to other androgens, of which andros-
terone is the most abundant in the fetus, followed by
3a-androstanediol and epiandrosterone [27]. Unlike rats,
human and sheep placentae have aromatase enzyme
that effectively metabolizes androgens to estrogens pre-
venting fetal exposure [22,25]. Similar findings of a lack
of increase in fetal testosterone levels, despite an
increase in maternal testosterone levels, is reported in
pregnant rats [27], guinea pigs [44], and sheep [22].
There are no reports on the fetal testosterone levels in
human IUGR and preeclamptic pregnancies, however a
20-fold increase in maternal testosterone levels is not
associated with changes in testosterone levels in cord
venous blood [48]. It appears that the placenta is an
effective barrier for testosterone under conditions of
moderate increases in maternal testosterone concentra-
tions. When the metabolizing capability of the enzymes
is exceeded, a significant increase in fetal testosterone
levels may occur, as observed in the dams exposed to
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Figure 4 Relative mRNA expression of system A amino acid
transporters in placenta of control and TP dams.T Pw a s
administered prenatally (0.5 mg/kg; gestational days 15-19) and (A)
slc38a1/Snat1, (B) slc38a2/Snat2 and (C) slc38a4/Snat4 mRNA
expression was assessed by real-time RT-PCR in the placenta obtained
from control (n = 6) and TP (n = 6) dams on GD 21. The mean mRNA
expression of the control group was assigned a value of 1 and the
mean of the TP group was calculated relative to the control group.
Values are given as mean ± SEM. *P <0 . 0 5versus control.
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Page 7 of 12higher maternal testosterone concentrations (TP 2.5 mg/
kg group) in our study. This finding may mean that
moderate increases in maternal testosterone concentra-
tions, as observed in the TP 0.5 mg/kg group, and
which occurs in most complicated human pregnancies,
do not cause fetal growth restriction by their direct
action on the fetus. In addition, testosterone is an ana-
bolic hormone, and one would anticipate an increased
testosterone concentration in the fetal environment to
facilitate growth rather than having a negative effect on
fetal growth. For example, testosterone exposure to
newborn pups by injection has shown to accelerate
growth rate [49]. These observations suggest that mater-
nal testosterone does not cross the placenta to exert
direct effect on fetal growth but rather may alter critical
functions that support fetal growth.
The circulating levels of glucose, triglycerides, cho-
lesterol, insulin, leptin, IGF-1 and thyroid hormones
are unaltered in testosterone-exposed pregnant animals
[22,23,30] suggesting that the observed effects of tes-
tosterone on fetal growth in this model may not be
secondary to metabolic changes. Theoretically,
increased maternal testosterone levels could reduce
fetal growth and birth weight through impaired placen-
tal function. This finding is substantiated by dimin-
ished uteroplacental perfusion and low fetal birth
weight by women who have increased testosterone
levels due to impaired placental aromatization [50,51].
In mammals, the major determinant of intrauterine
growth is the placental supply of nutrients to the fetus
[52]. The capacity of the placenta to deliver nutrients
to the fetus depends on a range of factors, including
its size, morphology, blood flow, transporter abun-
dance, and its rate of production of nutrients. The tes-
tosterone-exposed dams in this study have smaller
placentas when compared with those of control dams.
Similar reports of testosterone-induced reduction in
placental weights are reported in rats [27]. The reason
for smaller placenta in TP-exposed dams is not known
but may involve increased apoptosis or decreased pro-
liferation as reported in endothelial cells [53]. It is pos-
sible that high maternal testosterone leads to advanced
placental differentiation contributing for alteration in
placental weight/morphology [22].
Figure 5 Relative protein expression of system A amino acid transporters in placenta of control and TP dams.T Pw a sa d m i n i s t e r e d
prenatally (0.5 mg/kg; gestational days 15-19) and protein expression, as measured by Western blot analysis in homogenates from rat placenta
at GD 21 (n = 6, each group). Top panels show representative blots of the respective Snats and b-actin, and bottom panel is the summary of
densitometric results. The mean density of the control group was assigned a value of 1, and the mean density of the TP group was calculated
relative to the control group. Values are given as means ± SEM *P < 0.05 vs control.
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Page 8 of 12One of the important functions of the placenta is to
promote nutrient transport to the fetus. Glucose and
amino acids are essential for the developing fetus and,
as such, must be transported from the maternal circula-
tion through their transporters. It is well established
that the activity and/or expression of placental nutrient
and ion transporters are modified in human pregnancies
complicated by altered fetal growth [54]. The capacity of
the placenta to transport glucose is not altered in
human IUGR [55] but is increased in pregnancies com-
plicated by type-1 diabetes [56], which is associated with
accelerated fetal growth. In contrast, a number of pla-
cental transport systems for essential amino acids, such
as transporters for lysine, leucine and taurine [57], are
down-regulated in IUGR, whereas placental leucine
transport activity is increased in accelerated fetal growth
[58]. In the current study, glucose transport in vivo was
unaffected in this model, findings that are in line with
observations in human pregnancies complicated with
fetal growth inhibition [59] and models of placental
insufficiency in the rodent [60]. One placental amino
acid transport system that has attracted particular inter-
est in association with altered fetal growth is System A.
In the current study, placental System A transport activ-
ity in vivo was significantly reduced in testosterone-
exposed dams. Decreases in the mRNA and protein
expression of slc38a2/Snat 2 (but not of slc32a1/Snat1
and slc38a4/Snat4) in placental homogenates at GD 21
suggest that the reduced availability of transporters may
contribute to the observed transport changes. These
findings are in line with observations that Snat2 appears
to be a highly regulated Snat isoform, both in the pla-
centa [61-63] and in other tissues and cells, such as the
mammary gland [63] and 3T3-L1 adipocytes [64]. The
cellular mechanisms by which testosterone down regu-
lates placental Slc38a2/Snat2 remain to be fully estab-
lished. Decrease in non-essential amino acids levels was
found to be associated with increased expression of
Slc38a2/Snat2 and increased transport of MeAIB [65]. If
the reverse is true, that high amino acid concentrations
down-regulate system A activity, it cannot be excluded
that the moderate increase in essential amino acids
(lysine, histidine, leucine, isoleucine, and arginine), may
contribute to the down-regulation of Slc38a2/Snat2
expression and reduced MeAIB transport. Furthermore,
testosterone regulates mTOR activity in prostate cancer
cells [66]. Since mTOR signaling pathway regulates
amino acid transport in the placenta and that the activ-
ity of the placental mTOR pathway is reduced in IUGR
[67], it would be interesting to examine if testosterone
affect mTOR signaling. It is also possible that testoster-
one may indirectly regulate the expression and function
of transporters through other signaling mediators, such
as glucocorticoids, insulin, growth hormone, and leptin
[68]. Although we and others have shown that estradiol
levels were unaltered in pregnant rats [17] and sheep
[22] exposed to testosterone propionate, absence of
measures of conjugated estradiol or estradiol metabolites
cannot rule out the possible contribution of estradiol or
their metabolites to fetal growth restriction. An increase
in conjugated E2 in the maternal circulation, supportive
of increased aromatization, has been reported in prena-
tal testosterone-treated monkeys [69].
An additional decrease in the transport of amino acids
might occur because of a decreased availability of sub-
strate to the transporters as a result of a decreased
amino acid pool in the maternal circulation. Our studies
show that maternal plasma amino acid concentrations
are relatively maintained following testosterone expo-
sure, with the exception of decreases in glutamine, gly-
cine, tyrosine, serine, proline, and hydroxyproline and
increases in asparagine, isoleucine, lysine, histidine,
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Figure 6 Birth weight of pups and their anogenital distances in
control and TP groups. TP was administered prenatally (0.5 mg/kg;
gestational days 15-19) and (A) birth weight (n = 6 litters, each
group) and (B) anogenital distances were measured in both male
and female pups at term delivery (n = 6 litters, each group). Data
expressed as means ± SEM. *P < 0.05 vs controls.
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Page 9 of 12leucine and arginine. Studies have shown that testoster-
one promotes the increased utilization of hydroxyproline
leading to greater collagen deposition in smooth muscle
cells [70] which could have led to such dramatic reduc-
tions (-80%) in their plasma levels in TP exposed dams.
We cannot conclusively say that changes in the supply
of these amino acids are responsible for fetal growth
restriction in TP- exposed dams, since a deficiency of
one amino acid, in general, could be compensated for
by others unless it is rate-limiting. On the other hand,
studies have also demonstrated that suboptimal levels of
even single amino acids, such as taurine, can impair
normal fetal development [71]. These observations sug-
gest that the down regulation of placental amino acid
transporters, such as Snat2 and possibly the supply of
amino acids, especially glycine, serine and glutamine
which are substrates for system A transporter, may con-
tribute for the decreased amino acid supply to the fetus
and causes fetal growth restriction. It is surprising that,
despite increases in five essential amino acids and no
change in the majority of amino acids, that only reduc-
tion in four non-essential amino acids (transported by
Snat2) is associated with growth restriction. It is possible
that other essential amino acids transport mechanisms
may also play a role in fetal/neonatal growth restriction.
With a substantial reduction of the placental transport
of neutral amino acids at GD 21, the rapid fetal growth
(approximately 1 g day
-1) at this stage of gestation is dif-
ficult to sustain, which could understandably lead to
fetal growth restriction and delivery of low-birth-weight
pups at term. The consistent finding of a relationship
between placental System A and fetal growth in human
pregnancy [72,73] and the IUGR observed as a result of
inhibiting placental System A activity [74] support the
important role of placental system A activity in deter-
mining fetal growth.
Conclusions
In conclusion, the present study shows that an increase
in maternal testosterone in concentrations commonly
observed during pathological pregnancies caused a
marked reduction in maternal weight gain through the
dosing period until delivery and resulted in significantly
smaller than normal fetuses. A 2-fold increase in mater-
nal testosterone causes a significant decrease in fetal
size but does not elevate fetal testosterone. Thus, the
fetus appears to be protected from excess maternal
androgen perhaps due to effective enzymatic inactivation
by the placenta. Moreover, these studies demonstrate
that the specific downregulation of amino acid transpor-
ters within the placenta in response to TP treatment is
associated with a decrease in fetal growth. The decrease
in growth may be the result of a decrease of available
nutrients to the fetus.
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